CONCLUSIONS: GA was found to reduce relapses and clinical progression compared with placebo, and clinical progression in comparison with interferons. Serious adverse events were comparable with interferons. Qualitative and quantitative methods demonstrated that the benefits of GA outweigh the risks but the results differ substantially depending on the quantitative risk-benefit model used.
OBJECTIVES:
To assess the relative efficacy and safety of high (HD) and low dose (LD) beta interferons (IFN␤-1a and FN␤-1b) and glatiramer treatments in relapsingremitting multiple sclerosis. METHODS: Systematic review of literature. A bibliography search was carried out to identify primary studies on MEDLINE and EMBASE until February 2011. Other databases consulted were: Cochrane library, Centre for Reviews and Dissemination, ECRI, ISI Web of Knowledge e INHATA. Inclusion criteria: 1) head to head randomized clinical trials; 2) patients with relapsing-remitting multiple sclerosis; and 3) Outcomes: relapse rate, proportion of relapse-free patients, time to first relapse, expanded disability status scale, magnetic resonance imaging outcomes and adverse effects. A quality assessment was carried out to estimate the internal validity of the selected studies and the quality of their evidence. Indirect comparison were analysed when head to head studies weren't available. RESULTS: Eight studies were included in this report, 5 head to head studies between HD and LD IFN␤ and 3 studies which compared the HD beta interferons with glatiramer. No studies were found which compared LD beta interferon and glatiramer. The included studies had moderate internal validity. Direct comparison between the three beta interferons LD 1-a, HD1-a and HD1-b showed that all of them were effective and HD IFN␤ were better than LD IFN␤. There was weak indirect and direct evidence for similar efficacy between the HD IFN␤. The comparison HD interferons and glatiramer did not show significant differences in their relapse rate and MRI measures. CONCLUSIONS: 1) HD interferons showed greater efficacy at short term in reducing relapses than low-dose interferon. Currently, the estimation of the relative efficacy of two high-dose interferons is not possible but there is weak evidence in favor of similar efficacy, and 2) HD interferons and glatiramer showed similar efficacy for relapse measures at 2 years. 
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OUTCOMES OF ANTIEPILEPTIC DRUGS USES AT DOSES ABOVE THE RECOMMENDED RANGE AMONG CHILDREN WITH STRUCTURAL-METABOLIC EPILEPSY IN MALAYSIA
OBJECTIVES:
To assess the rate and clinical outcomes of using antiepileptic drugs (AEDs) at doses above the recommended range (DARR) in pediatric outpatients with structural-metabolic epilepsy. METHODS: Patients were followed-up retrospectively for one year since the first visit. Inclusion criteria were age Ͼ2 years; a diagnosis of structural-metabolic epilepsy; AEDs treatment; and three or more visits during the first year from the referral time. Exclusion criteria were epilepsy surgery within the first year from the referral time; and patients not satisfied inclusion criteria. During the period from January to June 2010, the required data were extracted from medical records. Assessment of AEDs doses was based on the recommended drug doses that were mentioned in "Pediatric Protocols for Malaysian Hospitals". RESULTS: Of 120 followed-up patients, only 13 (10.83%) of them exposed to AEDs at DARR. In term of visits, 32 (5.68%) visits out of 563 demonstrated DARR. There was no association between the uses of AEDs at DARR with age, gender, race, child development, and seizure type. However, the uses of AEDs at DARR were significantly higher in polytherapy than monotherapy visits (Chisquare, pϽ0.001). Visits included DARR led to higher seizure frequency than visits without DARR (Mann-Whitney, Pϭ0.001). Ultimately, only patients who weren't exposed to AEDs at DARR showed a significant improvement in their seizure control at the last follow-up visit compared with the baseline (Wilcoxon, Pϭ0.001). CONCLUSIONS: The low frequency of DARR indicates the knowledgeability and awareness of the in charged pediatric neurologist about consequences of exceeding average effective doses. In term of better seizure control, uses of AEDs at DARR shows no benefit over using these agents at recommended doses. Mean EDSS scores at 2, 5 and 10 years post-onset were estimated at 1.05, 2.55 and 3.21 for SOT and 0.95, 2.13 and 3.07 for non-SOT, respectively. CONCLUSIONS: The analysis suggests that RRMS patients who experience relapse and MRI activity despite previous treatment with a DMT face faster progression to severe disability states. The analysis highlights the importance of effective treatment options for these patients.
PND7 DISABILITY PROGRESSION IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) WHO EXPERIENCE DISEASE ACTIVITY DESPITE PREVIOUS DISEASE MODIFYING THERAPY
PND8 PREVALENCE AND PROCEDURE FOR VERTIGO FOLLOW-UP IN FRANCE
Taieb C 1 , Ruiz F 2 , Mansuy L 3 1 PFSA, Boulogne Billancourt, France, 2 Clinsearch, Bagneux, France, 3 Pierre Fabre, Toulouse, France OBJECTIVES: Vertigo is a crippling and stressful symptom. It involves the illusion of movement that manifests itself with an impression of spinning. It is often accompanied by neurovegetative signs, but the patient remains conscious during the attack. Vertigo, often recurrent and sometimes persistent, can strongly alter the quality of life of patients, to the point of preventing the performance of the majority of daily activities. It increases the risk of falling and depression or anxiety. Describe the initial care of patients with vertigo by general practitioners in France. METHODS: A total of 1400 general practitioners drawn by lot from the general practitioners practicing in France were contacted, then questioned. RESULTS: The prevalence of consultations for vertigo and, this being any type of vertigo, is 5.57%, with one in three is being recurrent vertigo, with an incidence of 2.49%. 45% of the vertigo cases were not associated with an underlying known pathology (for example, a middle ear infection or brain tumour), 40 % of the benign paroxysmal positional vertigos, 9% Ménière's disease, 6% a vestibular neuronitis or neuritis 69% of cases of recurrent vertigo not associated with an underlying pathology are treated by oral an anti-vertigo drugs, 4% are intravenous, 27% benefit from 2 galenic. Fiftyseven percent of the general practitioners directly treat their patients' vertigo, the others refer them to a specialist. CONCLUSIONS: The epidemiology of recurrent vertigo (upon the first appearance) has not been studied. It is necessary to point out that vertigo is, for the most part, recurrent. The interest in this work responds to this problem situation. 
PND9 THE ROLE OF SPONTANEOUS EVENTS DATABASES FOR BENEFIT-RISK ANALYSIS
OBJECTIVES:
We used the World Health Organisation database (Vigibase) to evaluate the contribution of a global spontaneous adverse event (AE) database for an analysis of benefit-risk for Glatiramer acetate (GA) in multiple sclerosis. METHODS: Vigibase is a passive surveillance system that in 2011 contained over 6 million reports of spontaneous AEs suspected of being linked to health care products from regulatory authorities in nearly 90 countries. GA, interferon beta-1a, interferon A318 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 -A 5 1 0
